Pfizer Announces Positive Top-Line Results from Phase III Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

Pfizer announced positive top-line results from its pivotal EU Phase III study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease, pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine for the pediatric population.